In our study, fifty-two 3-week-old puppies (18 to 21 days of age) were administered a 1cc dose of NEOPAR®. Prior to vaccination, a blood sample taken from each of the 52 puppies indicated pre-existing CPV (canine parvovirus) maternal antibodies were present (range: 32 to 3,162; average of 522).

Independent researchers have reported that a CPV maternal antibody titer of 20 or higher can block conventional vaccines from stimulating protection. Fourteen days after vaccination (at five weeks of age), a second blood sample was collected to determine the level of vaccine-induced CPV antibody. Ninety percent of the puppies had a positive vaccine-induced CPV antibody response to only one dose of NEOPAR®. A positive vaccine-induced CPV antibody response is defined as having at least a 4-fold increase in the antibody level between the before and the 14-day post-vaccination blood sample.

neotech neopar

Yes, even in the presence of high maternal antibodies, NEOPAR® induced a high protective level of CPV antibodies against the #1 viral disease of puppies.

 Click on the following button to learn more about NeoPar!


For more information, don't hesitate to contact Dr. Ben Hatler at This email address is being protected from spambots. You need JavaScript enabled to view it. or by calling 1.877.636.8324.